BUZZ-Lisata jumps as Kuva Labs strikes acquisition deal
I'm PortAI, I can summarize articles.
Shares of Lisata Therapeutics surged 85% to $3.99 in premarket trading after the company announced an acquisition deal with Kuva Labs for $4 per share in cash, plus potential milestone payments of $2 per share. The offer represents an 85% premium to the last closing price and could reach a 180% premium if milestones are achieved. The deal has been unanimously approved and is expected to finalize before February 27, pending shareholder approval. Lisata's lead drug, certepetide, is under trial for enhancing cancer treatment efficacy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments